Stock PHAR PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company Pharming Group N.V. Nasdaq

Equities

PHAR

US71716E1055

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
7.68 USD -12.23% Intraday chart for Pharming Group N.V. -17.24% -32.81%
May. 31 Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug MT
May. 30 Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union CI

Business Summary

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.

Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.

Number of employees: 382

Sales per Business

EUR in Million2022Weight2023Weight Delta
Recombinant Human C1 Esterase Inhibitor
100.0 %
196 100.0 % 227 100.0 % +15.98%

Sales per region

EUR in Million2022Weight2023Weight Delta
United States
97.5 %
190 97.3 % 221 97.5 % +16.17%
Europe and Rest of World
2.5 %
-- 6 2.5 % -

Managers

Managers TitleAgeSince
Sijmen de Vries CEO
 Chief Executive Officer 65 08-10-12
Jeroen Wakkerman DFI
 Director of Finance/CFO 55 20-11-15
Anurag Relan CTO
 Chief Tech/Sci/R&D Officer 52 -
Mireille Sanders COO
 Chief Operating Officer 56 19-04-30
Ruud van Outersterp CMP
 Compliance Officer 60 20-03-31
Michael Levitan IRC
 Investor Relations Contact 66 -
Stephen Toor PRN
 Corporate Officer/Principal 52 20-12-14

Members of the board

Members of the board TitleAgeSince
Mark Pykett BRD
 Director/Board Member 60 20-12-10
Leonard Kruimer BRD
 Director/Board Member 66 21-05-18
Sijmen de Vries CEO
 Chief Executive Officer 65 08-10-12
Steven Baert BRD
 Director/Board Member 50 21-03-31
Deborah Jorn BRD
 Director/Board Member 66 19-05-21
Barbara Yanni BRD
 Director/Board Member 69 20-12-10
Jabine T. M. van der Meijs BRD
 Director/Board Member 58 21-05-18
Richard Peters CHM
 Chairman 61 23-09-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 673,441,363 657,631,963 ( 97.65 %) 0 97.65 %

Shareholders

NameEquities%Valuation
RTW Investments LP
2.984 %
20,027,808 2.984 % 19 M $
Acadian Asset Management LLC
2.803 %
18,809,884 2.803 % 18 M $
DWS Investment GmbH
1.483 %
9,952,706 1.483 % 9 M $
Sijmen de Vries
1.281 %
8,594,721 1.281 % 8 M $
Medical Strategy GmbH
0.4169 %
2,797,986 0.4169 % 3 M $
Apo Asset Management GmbH
0.2624 %
1,760,903 0.2624 % 2 M $
LSP Advisory BV
0.2078 %
1,394,628 0.2078 % 1 M $
Mandarine Gestion SA
0.1788 %
1,200,000 0.1788 % 1 M $
Mireille Sanders
0.1191 %
799,020 0.1191 % 748 842 $
Financière Arbevel SA
0.0806 %
540,900 0.0806 % 506 931 $
NameEquities%Valuation
Cowen Prime Advisors LLC
0.0335 %
22,460 0.0335 % 234 707 $
Silverberg Bernstein Capital Management LLC
0.0264 %
17,710 0.0264 % 185 070 $
Morgan Stanley Capital Services LLC
0.004172 %
2,800 0.004172 % 29 260 $
UBS Securities LLC
0.000077 %
52 0.000077 % 543 $

Company contact information

Pharming Group NV

Darwinweg 24

2333 CR, Leiden

+31 71 524 7400

http://www.pharming.com
address Pharming Group N.V.(PHAR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Pharming Group N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.808 EUR
Average target price
1.917 EUR
Spread / Average Target
+137.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.69% 750B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 606B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.87% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.74% 326B
ABBVIE INC. Stock AbbVie Inc.
+6.76% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.08% 246B
ROCHE HOLDING AG Stock Roche Holding AG
-3.44% 213B
NOVARTIS AG Stock Novartis AG
+11.35% 213B
PFIZER, INC. Stock Pfizer, Inc.
+2.64% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PHARM Stock
  4. PHAR Stock
  5. Company Pharming Group N.V.